DMRA Financials

Income Statement
MetricQ2 2026Q1 2026
Revenue
0
0
Cost of Revenue
0
0
Gross Profit
0
0
Operating Expenses
35.0M
+13.6%
30.8M
R&D
25.5M
+7.4%
23.8M
SG&A
9.5M
+34.4%
7.0M
Operating Income
-34994000
-13.6%
-30811000
EBITDA
-34988000
-13.6%
-30806000
Net Income
-31174000
-12.2%
-27783000
EPS (Basic)
$-0.39
+37.1%
$-0.62
EPS (Diluted)
$-0.39
+37.1%
$-0.62
Shares (Diluted)
61.1M
+78.2%
34.3M
Damora Therapeutics (DMRA) โ€” Financials